This peer-reviewed research article, published in Human Vaccines & Immunotherapeutics, evaluates the cost-effectiveness of introducing the 23-valent pneumococcal polysaccharide vaccine (PPV23) for older adults into the provincial immunization program in Zhejiang province, China. Conducted by researchers from the Yinzhou District Center for Disease Control and Prevention and the Zhejiang Provincial Center for Disease Control and Prevention, the study uses a decision tree–Markov model from a societal perspective to compare one-dose PPV23 vaccination (at 90% coverage) versus no vaccination among cohorts aged 60 and 70 years. The model incorporates invasive pneumococcal disease (IPD) and non-bacteremic pneumococcal pneumonia (NBP), estimates quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs), and applies both one-way and probabilistic sensitivity analyses.
How can the findings be used?
These findings provide economic evidence to inform provincial or national decisions on including PPV23 in immunization programs for older adults in China. They also offer parameters and modeling approaches that may support economic evaluations of adult pneumococcal vaccination in similar middle-income settings.
Thumbnail image credit: Shutterstock / Yusnizam Yusof
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.